{
  "url": "https://www.morningstar.com/news/globe-newswire/9519338/tevogen-bio-highlights-proprietary-assets-and-upcoming-valuation-disclosure",
  "authorsByline": "",
  "articleId": "2fe8513a33844ec3955ce4f9de895656",
  "source": {
    "domain": "morningstar.com",
    "location": {
      "country": "us",
      "state": "IL",
      "county": "Cook County",
      "city": "Chicago",
      "coordinates": {
        "lat": 41.8755616,
        "lon": -87.6244212
      }
    }
  },
  "imageUrl": "https://images.contentstack.io/v3/assets/blt4eb669caa7dc65b2/blta7dd42ebdd7b93b8/61899b34a3c7df383578294c/morningstar-og.png",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-27T14:20:00-05:00",
  "addDate": "2025-08-27T20:10:34.916879+00:00",
  "refreshDate": "2025-08-27T20:10:34.916881+00:00",
  "score": 1.0,
  "title": "Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure",
  "description": "Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure  Morningstar",
  "content": "WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen (\u201cTevogen Bio Holdings Inc.\u201d or \u201cCompany\u201d) (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under U.S. GAAP accounting rules are not reflected on the Company\u2019s balance sheet, yet represent substantial long-term value. Tevogen will provide detailed information and valuation of these assets in the coming days.\n\u2022 Intellectual Property Portfolio \u2013 Three wholly owned, granted U.S. patents and twelve pending U.S. patents, including two in artificial intelligence.\n\u2022 Artificial Intelligence Technology & Partnerships \u2013 Strategic collaborations with Microsoft and Databricks supporting:\n\u2022 PredicTcell\u2122, AI algorithms predicting peptide\u2013T cell receptor interactions, accelerating development and expanding Tevogen\u2019s pipeline.\n\u2022 AdapTcell\u2122, AI models decoding HLA\u2013T cell interactions, furthering immune system insights and reveal new therapeutic paths.\n\u2022 Clinical Pipeline \u2013 Therapeutics designed to treat cancers while enabling patients to continue oncology care, with opportunistic expansion into non-oncology indications leveraging ExacTcell.\n\u2022 Funding and Cash Reserves \u2013 Access to line of credit and well-capitalized for current operations.\n\u2022 Facilities \u2013 Drug discovery lab at CIC Philadelphia and headquarters in New Jersey. Ongoing efforts to establish internal GMP manufacturing capabilities.\n\n\n\n\n\n\"The accounting treatment of internally developed assets may not fully capture their value, but our wholly owned intellectual property, proprietary platforms, advanced AI technologies, strategic partnerships, discovery lab, and manufacturing facility in development are foundational drivers of Tevogen\u2019s growth and long-term value creation,\" said Dr. Ryan Saadi, Tevogen\u2019s Founder and CEO.\n\nThis press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen\u2019s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen\u2019s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as \u201cmay,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cgoal,\u201d \u201copportunity,\u201d \u201cproject,\u201d \u201cbelieve,\u201d \u201cfuture,\u201d and similar words and expressions or their opposites. These statements are based on management\u2019s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company\u2019s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.\n\nFactors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen\u2019s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen\u2019s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen\u2019s limited operating history; and those factors discussed or incorporated by reference in Tevogen\u2019s Annual Report on Form 10-K.\n\nYou should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.",
  "medium": "Article",
  "links": [
    "https://www.globenewswire.com/Tracker?data=WkKl2ijshbb6XaBPeP6On1pqzEiCaDQUf_H60mnJ9Xh747hqUlJMbhMw9OQKcBglGcnpDjNCcpZmoASGm17Gn1wTTRilyMApKfmEYQdXnhl924F7MpivA2zl3K_bzrwo",
    "https://www.globenewswire.com/Tracker?data=Qu9VUIrrJ7JLOM46Z27uwiPc9npiREwyCdKZn-8EXChsfxDnHdoGixWX4lN0bXmo6XVT3q1MM_yjeRgBJTGKFw==",
    "https://www.globenewswire.com/NewsRoom/AttachmentNg/679fef4d-f32f-46a2-9452-c31af5cf4597"
  ],
  "labels": [],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Tevogen",
      "weight": 0.09137913
    },
    {
      "name": "Tevogen Bio",
      "weight": 0.090508044
    },
    {
      "name": "Tevogen Bio Holdings Inc.",
      "weight": 0.08189592
    },
    {
      "name": "unsuccessful new products",
      "weight": 0.05675613
    },
    {
      "name": "rapid technological developments",
      "weight": 0.056532916
    },
    {
      "name": "commercial development",
      "weight": 0.056527276
    },
    {
      "name": "development",
      "weight": 0.054729167
    },
    {
      "name": "other factors",
      "weight": 0.05457578
    },
    {
      "name": "other expectations",
      "weight": 0.053920362
    },
    {
      "name": "new therapeutics",
      "weight": 0.053486954
    }
  ],
  "topics": [],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.9873046875
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.9560546875
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.95166015625
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.94384765625
    }
  ],
  "sentiment": {
    "positive": 0.62244844,
    "negative": 0.020284005,
    "neutral": 0.35726756
  },
  "summary": "Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has updated investors of its significant internally developed assets, which are not reflected on the company's balance sheet but represent substantial long-term value. The company will provide detailed information and valuation of these assets in the coming days. The assets include three wholly owned, granted U.S. patents and twelve pending U.K. patents, including two in artificial intelligence. The Company's clinical pipeline includes Therapeutics designed to treat cancers while enabling patients to continue oncology care. Funding and Cash Reserves include a drug discovery lab at CIC Philadelphia and headquarters in New Jersey. This press release contains forward-looking statements, including statements about Tevogen\u2019s plans for its research and manufacturing capabilities, future growth, and potential benefits of its product candidates for the treatment of infectious diseases and cancer. These statements are subject to numerous factors including unknown unknownities, delays, uncertainties, and other factors not under control.",
  "shortSummary": "Tevogen Bio Holdings Inc. highlights significant internally developed assets with significant long-term value and potential challenges, including potential drug development and manufacturing challenges.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": true,
  "reprintGroupId": "44d42beeee7c4966b7259481f580acbf",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://www.globenewswire.com/Tracker?data=Qu9VUIrrJ7JLOM46Z27uwiPc9npiREwyCdKZn-8EXChsfxDnHdoGixWX4lN0bXmo6XVT3q1MM_yjeRgBJTGKFw==",
      "text": "A healthier world is possible when lifesaving innovations are within the reach of all\nThat\u2019s why we aspire to be the first biotechnology company offering commercially attractive, economically viable, and cost-effective personalized T cell therapies\nWe are a clinical-stage specialty immunotherapy company leveraging our ExacTcellTM technology platform to harness the power of CD8+ cytotoxic T lymphocytes, one of nature\u2019s most powerful immunological weapons, to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders, with the aim of addressing the significant unmet needs of large patient populations.\nTarget antigens present only on diseased cells, allowing healthy cells to remain intact\nAntigens engaged by naturally occurring T cell receptors -enhanced safety\nDiverse applications spanning oncology, neurology, & virology\nWelcome to the forefront of innovation in the biotech industry, where human expertise and artificial intelligence merge to redefine the limits of scientific exploration\nTevogen.AI is exploring ways that we may deploy artificial intelligence to power target detection to further accelerate our product development pace, enabling us to relay the resulting savings directly to the patients.\nInvestor Relations\nPurpose, innovations, and opportunity to join before Tevogen\u2019s next growth spurt\nMessage From the CEO\nTevogen was created based on the audacious goal of finding a cure for cancer. This dream inspired us to pursue the development of life-saving therapies for some of the most prevalent illnesses plaguing humanity today.\nOur success is rooted in passion and perseverance, and is backed by rigorous science. However, our unrelenting optimism \u2013 and belief that learning and adapting means improving \u2013 is what propelled us to this moment.\nOur corporate culture encourages people to contribute their unique and diverse perspectives, to harness their optimism and creativity, and to be ready to learn and develop solutions together towards a common and greater purpose. We all are different and think differently, it\u2019s okay to fail and make mistakes but learn from the failures \u2013 that mindset, respect for each other and irrational optimism is what has made Tevogen a reality.\nI am confident in Tevogen\u2019s success, and in our investigational therapies. We have brought together accomplished experts in immunotherapy and biopharma business to contribute their knowledge in a practical and efficient way. Tevogen is uniquely positioned to combat several large-scale health problems of today, including COVID-19. I am equally confident in our rapidly advancing and diverse research portfolio in virology, oncology, and neurology.\nOne of our objectives is to ensure that all people, regardless of socioeconomic status, are able to afford our therapies. Tevogen\u2019s aim is to be the first biotech to offer personalized T cell therapeutics at commercially attractive and economically viable price. As the founder of Tevogen and its CEO, I am personally delighted to see that what started as an intrepid goal may very well play a critical role in overcoming the biggest public health crisis of our time.\nRyan Saadi, MD, MPH\nCEO, Tevogen Bio\n\u00a9 2025 Tevogen Bio. All Rights Reserved."
    }
  ],
  "argos_summary": "Tevogen Bio Holdings Inc. disclosed that it holds substantial internally developed assets\u2014such as a portfolio of 15 U.S. patents, AI platforms PredicTcell\u2122 and AdapTcell\u2122, and strategic collaborations with Microsoft and Databricks\u2014that are not reflected on its balance sheet but represent long\u2011term value. The company highlighted its clinical pipeline of off\u2011the\u2011shelf T\u2011cell therapies for cancer and potential non\u2011oncology indications, along with plans to establish GMP manufacturing and a discovery lab at CIC Philadelphia. Tevogen remains well\u2011capitalized with a line of credit and is confident in its ability to bring affordable, personalized T\u2011cell treatments to market. The release also cautions that forward\u2011looking statements are subject to risks such as funding needs, regulatory approvals, and competitive dynamics.",
  "argos_id": "60AFYS6E2"
}